Evidence map›Paper›PMID 41041529›Full record

ArticleResearch square2025

Comparing the predictive value of plasma p-tau217 and CSF biomarkers (p-tau181, Aβ42) using amyloid positron emission tomography in Alzheimer's continuum.

Mohammad Hossein Azaraein, Elham Zarrazvand, Fatemeh Heydari, Nasim Asimi, Elham Ramezannezhad, Deniz Rahimipour, Kimia Janeshin, Aida Mahdian, Maryam Fallahpour Sichani, Shaghayegh Farhadi and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohammad Hossein AzaraeinShahid Sadoughi University of Medical Sciences and Health Services.
Elham ZarrazvandTehran University of Medical Sciences.
Fatemeh HeydariQom Islamic Azad University.
Nasim AsimiIslamic Azad University, Tehran.
Elham RamezannezhadIsfahan University of Medical Science.
Deniz RahimipourIran University of Medical Sciences.
Kimia JaneshinShahid Beheshti University of Medical Sciences.
Aida MahdianKashan University of Medical Sciences.
Maryam Fallahpour SichaniIslamic Azad University, Tehran.
Shaghayegh FarhadiIslamic Azad University Sanandaj Branch.
Razieh ZamiriUniversity of Padua.
Mohammad Amir AmirianKashan University of Medical Sciences and Health Services.
Maryam BemanalizadehNeuroTRACT Association, Tehran University of Medical Sciences.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

introductionThis study explores the diagnostic accuracy of different biomarkers for Alzheimer's disease (AD) using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

methodsA cross-sectional analysis was performed on individuals with mild cognitive impairment. Key biomarkers assessed included plasma p-tau217, CSF p-tau181, CSF Aβ42, and amyloid PET imaging, alongside clinical assessments using the Clinical Dementia Rating (CDR) and the Alzheimer's Disease Assessment Scale (ADAS).

resultsPlasma p-tau217 showed the strongest correlation with amyloid-β deposition and clinical scores (Adjusted R DISCUSSION: These results suggest that plasma p-tau217 may serve as a more accurate, cost-effective, and non-invasive alternative to CSF biomarkers and PET imaging. Its superior predictive power highlights its potential in routine clinical settings for early diagnosis and monitoring of AD progression, addressing key challenges in accessibility and patient compliance associated with current diagnostic methods.

Indexed as

Alzheimer’s Diseasecerebrospinal fluid biomarkerscognitive impairmentPhosphorylated-tauPlasma biomarkerPositron emission tomographyβ-amyloid

Identifiers

PMID41041529
PMCPMC12486070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.